Jul 19 2024 This Week in Cardiology

Vulnerable plaque and scientific method; industry payments to trainees; tirzepatide or semaglutide; trial interpretation; and PFA are the topics John Mandrola, MD, covers in today’s podcast.

This podcast is intended for healthcare professionals only.

To read a partial transcript or to comment, visit:

https://www.medscape.com/twic

I. Non-invasive Imaging for Vulnerable Plaque  

PET Imaging Finds Vulnerable Plaques That Cause MI

https://www.medscape.com/viewarticle/pet-imaging-finds-vulnerable-plaques-cause-mi-2024a1000cm2

• JACC paper https://doi.org/10.1016/j.jacc.2024.03.419
• Original JAMA-Card paper https://jamanetwork.com/journals/jamacardiology/fullarticle/2806690

II. Industry Payments to Fellows

• JAMA Network Letter https://jamanetwork.com/journals/jamainternalmedicine/article-abstract/2821267

III. GLP-1a Class Effect?

Semaglutide Significantly Improves Chronic Kidney Disease

https://www.medscape.com/viewarticle/semaglutide-significantly-improves-chronic-kidney-disease-2024a10009w9

Mounjaro Beats Ozempic, So Why Isn’t It More Popular?

https://www.medscape.com/viewarticle/mounjaro-beats-ozempic-so-why-isnt-it-more-popular-2024a1000ckd

• JAMA-Internal Medicine: Semaglutide vs Tirzepatide https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/2821080 
• SELECT trial https://www.nejm.org/doi/full/10.1056/NEJMoa2307563
• FLOW trial https://www.nejm.org/doi/full/10.1056/NEJMoa2403347
• SURPASS-CVOT – Rationale https://doi.org/10.1016/j.ahj.2023.09.007

IV. Colchicine and Trial Interpretation in the Lancet

• CONVINCE https://doi.org/10.1016/S0140-6736(24)00968-1

V. PFA

Pulsed Field Ablation for AF: Are US Electrophysiologists Too Easily Impressed?

https://www.medscape.com/viewarticle/pulsed-field-ablation-af-are-us-electrophysiologists-too-2024a1000d2v

You may also like:

The Bob Harrington Show with the Stephen and Suzanne Weiss Dean of Weill Cornell Medicine, Robert A. Harrington, MD. https://www.medscape.com/author/bob-harrington

Questions or feedback, please contact news@medscape.net